Clarissa Desjardins
Angel Investor
Montréal, Canada
Clarissa Desjardins is a Series A investor in Montréal focused on Medical and Biotechnology. Dr. Desjardins is the Founder and CEO of the Clementia Pharmaceuticals Inc. Previously, Clarissa was CEO at the Center of Excellence in Personalized Medicine, a federally and privately-funded non-for-profit created to promote personalized medicine through education, policy, and public-private research partnerships. Prior to this, Clarissa had beena serial entrepreneur, taking part in all aspects of company creation, from conception to financing, to the marketplace. She was the founder of Advanced Bioconcept which was sold to NEN Life Sciences (Perkin Elmer) in 1998. She also co-founded Caprion Pharmaceuticals Inc., a biotechnology company focused on proteomic biomarker discovery and drug development where she was executive Vice-President of Corporate Development. Clarissa received the BRIO award for outstanding contributions to the biotechnology industry from the Quebec Biotechnology Association, was nominated to Ernst & Young’s Entrepreneur of the Year award and was one of Canada’s top young Canadians likely to influence the future by the Globe and Mail. She has been a Board Member on numerous private and public companies including most recently the scientific advisory board of the Canadian Council of Academies. She earned a Ph.D. in Neurology and Neurosurgery from McGill’s Faculty of Medicine, and was a Medical Research Council postdoctoral fellow at the Douglas Hospital Research Centre.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Clarissa Desjardins invests in
Stages Clarissa Desjardins invests in
Countries Clarissa Desjardins invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $49.6M / Series A / Feb 08, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Clarissa Desjardins invest in?
Clarissa Desjardins invests primarily in Medical and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Clarissa Desjardins?
Public channels for Clarissa Desjardins include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Clarissa Desjardins last invest?
The most recent investment recorded for Clarissa Desjardins closed in Feb 2022. Shizune tracks 1 investment in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
